Peanut allergy prevalence in Australian children has risen to 3% in recent years. Despite the risk of potentially fatal reactions, there is currently no method available in routine clinical practice for treating peanut allergies. This exciting opportunity will be focused around our established robust murine peanut-induced anaphylaxis model that will be used to test an immunotherapic approach which aims to selectively inhibit the production of peanut allergen-specific antibodies and decreases the risk of anaphylaxis during the desensitization process. This type of immunotherapy could have broad application in treating allergic diseases. The total scholarship package is $25,849 per annum for three years.
New clinical applications for biomaterial implants are rapidly emerging, and novel approaches to their manufacture and the material from which they will be constructed from are warranted. This is because they need to be able to interact favourably with the body’s defence systems and this project aims to achieve this goal using nanotechnology.
UniSA are offering the opportunity to work on a project that aims to provide a mechanistic understanding of how surface nanotopography affects inflammatory responses. We have experimental evidence demonstrating that engineered surface nanotopography in combination with surface chemistry downregulates the expression of proinflammatory cytokines from primary macrophages. These exciting findings are important because they show that it may be possible to engineer the nanotopography of a biomedical device surface in a manner which leads to a desired and predictable level of inflammation and subsequent foreign body reaction (FBR) medical implants and tissue engineering constructs. The total scholarship package is $25,849 per annum for three years.
The Experimental Therapeutics Laboratory is a collaborative venture between scientists from the Sansom Institute for Health Research (University of South Australia), the Hanson Institute and the Cancer Clinical Trials Unit (Royal Adelaide Hospital Cancer Centre).
We perform basic, translational and clinical research that aims to improve chronic and acute health outcomes by exploring novel immunotherapeutic approaches to treat and prevent cancer, allergy and other diseases including chronic and acute infections. Our expertise exploits the specificity and power of the immune system to design, develop, and implement cutting edge approaches to new diagnostics and therapeutic agents.
Associate Professor John Hayball is a molecular and cellular immunologist with fundamental interests understanding the processes that control immunological tolerance and immunity in different animal species ranging from the teleost fishes through to humans. He heads the Experimental Therapeutics Laboratory (Sansom Institute) and holds a tenured (A/Prof) academic appointment at UniSA. He has a strong track record of project grant funding awarded from a variety of traditional sources including NHMRC and ARC and other national, state and institutional schemes He has also a long history of highly successful industry engagement, including biotechnology consultancies, commercial research funding and funding from industry-leveraged federal government schemes including ARC Linkage and the Researches-in-Business (Enterprise Connect) schemes. Most recently, he has received $3mil in research funding from emerging biotechnology company Sementis Pty Ltd to develop from first principles new vaccines for cancer, allergy and infectious disease applications..